New Treatments for Patients With Progressive Metastatic Urothelial Carcinoma

H&O Does urothelial carcinoma pose any challenges or opportunities for the development of new drugs? JR Urothelial carcinoma tends to affect older patients, who often have […]

Bladder-Sparing Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer

Abstract: Bladder-sparing therapies for the treatment of nonmetastatic muscle-invasive bladder cancers are included in both American and European guidelines. Numerous treatment approaches have been described, […]

Update on Perioperative Systemic Therapy for Urothelial Carcinoma

Abstract: Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint […]

Immunotherapy in Urothelial Cancer, Part 2: Adjuvant, Neoadjuvant, and Adjunctive Treatment

Abstract: Urothelial cancer, which is predominantly seen in men, is common throughout the world. Most disease presents as non–muscle invasive bladder cancer (NMIBC), with cancer […]

Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease

Abstract: Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this […]

New Treatments for Bladder Cancer

H&O How common is bladder cancer? NH Bladder cancer is very common in the United States; it is the fifth most common cancer diagnosed in this […]

Bladder Cancer: Advances in Treatment and Research

H&O What is the background on bladder cancer and the current state of this disease? MG Bladder cancer affects approximately 70,000 patients a year in the United States […]